Related Experiment Video

Updated: Aug 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Design and characterization of a new class of inhibitors of ras activation

Sonia Colombo1, Francesco Peri, Renata Tisi

  • 1Laboratory of Molecular Biology, Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, Milan 20126, Italy.

Annals of the New York Academy of Sciences
|January 22, 2005
PubMed

Insights

Researchers developed novel Ras inhibitors to combat cancer by targeting Ras signaling pathways. These new molecules aim to improve upon existing inhibitors

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras proteins regulate cell proliferation via GTP/GDP binding and are frequently mutated in human cancers.
  • Targeting Ras activation is a promising strategy for developing antineoplastic drugs, as ~30% of human tumors harbor oncogenic Ras mutations.
  • Previous inhibitors targeting Ras nucleotide exchange showed limitations in solubility and stability.

Purpose of the Study:

  • To design and synthesize novel Ras inhibitors with improved solubility and chemical stability.
  • To evaluate the efficacy of these new molecules in inhibiting Ras nucleotide exchange both in vitro and in vivo.
  • To explore alternative therapeutic strategies for inhibiting Ras-driven cancer cell proliferation.

Main Methods:

  • Synthesis of novel bioactive molecules based on existing Ras nucleotide exchange inhibitors.
  • In vitro characterization using purified human and yeast Ras proteins to assess inhibition of nucleotide exchange.
  • In vivo evaluation using Saccharomyces cerevisiae strains to determine efficacy and stability.

Main Results:

  • The synthesized molecule SCH-53870 demonstrated inhibition of p21-hRas nucleotide exchange in vitro.
  • SCH-53870 exhibited poor water solubility and rapid degradation in aqueous solutions, limiting its in vivo potential.
  • Newly designed and synthesized molecules showed improved solubility and stability, with promising in vitro and in vivo activity.

Conclusions:

  • Novel Ras inhibitors with enhanced solubility and stability were successfully designed and synthesized.
  • These compounds represent potential therapeutic agents for Ras-driven cancers.
  • Further research on these molecules may lead to alternative therapies targeting transformed cell proliferation.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...